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Introduction
Epigenetic alterations often promote or even drive cancer development by activating and sustaining cancer-promoting gene expression. 1 Among epigenetic changes in cancer cells, histone lysine methylation/demethylation has gained substantial attention as a possible target in therapeutic drug development. 2 Histone lysine methylation/demethylation is extensively involved in nucleosome remodeling and gene expression. Lysine residue methylation is reversibly regulated by histone lysine methyltransferases and histone lysine demethylases (KDMs). Several KDMs have so far been identified, and lysine-specific demethylase 1 (KDM1A/LSD1) has received increasing attention since its identification in 2004. 3 Overexpression of KDM1A is frequently observed in prostate, breast, and bladder cancers, neuroblastoma, and especially hepatoma 4 , where it correlates directly with adverse clinical outcome and inversely with differentiation. 5 Thus, KDM1A inhibitors are of clinical interest for their anticancer role as well as their potential application in other human diseases that exhibit deregulated gene expression. 6 Among other members of the KDM family, KDM5A/JARID1A is of particular interest because it specifically removes a methyl group from the trimethylated lysine 4
of histone H3 to produce dimethylated lysine 4. This produces a substrate for KDM1A, which is cooperatively capable of removing dimethyl and monomethyl groups from lysine 4 of histone H3. 6, 7 KDM1A and KDM5A are recruited to chromatin through the CoREST 6 and ORC2-SUMO2 8 complexes, respectively. Hence, these KDMs are generally recognized as nuclear-localized proteins. 9, 10 KDM1A is a flavin adenine dinucleotide-containing enzyme belonging to the amine oxidase superfamily. 11 Structural homology between KDM1A and monoamine oxidase-B, a clinically validated pharmacological target, suggests that KDM1A is a druggable target. Indeed, screening of known monoamine oxidase inhibitors has uncovered KDM1A inhibitors that are effective at sub-millimolar concentrations, among which the best known is the clinically used antidepressant drug
trans-2-phenylcyclopropylamine (TCP). Multiple clinical trials have begun to
investigate the antitumor effect of TCP. 12 Recently, we reported that all-trans geranylgeranoic acid (GGA), a natural acyclic diterpenoid found in medicinal herbs 13 , inhibits KDM1A activity at the same IC 50 as that of TCP. 14 GGA has been reported to induce cell death in several human hepatoma cell lines. 13, 15 Incomplete autophagic response 16 , nuclear translocation of the cytoplasmic p53 17 , and endoplasmic reticulum stress response 18 have been explored as potentially being involved in GGA-induced cell death. Indeed, the 4,5-didehydro derivative of GGA has been repeatedly investigated and demonstrated to potentially prevent second primary hepatoma in clinical trials. [19] [20] [21] [22] To our knowledge, no studies have yet reported KDM1A inhibitor-induced changes in the subcellular distribution of the enzyme. When studying the effects of GGA on hepatoma cells, we found that GGA altered the subcellular localization of KDM1A, which could be important for both KDM1A-inhibitor screening and understanding KDM1A biology. Here, we report that some KDM1A-inhibitors can remove KDM1A from chromatin and move it to the cytoplasmic space in human hepatoma cells. 
Results

Cytoplasmic
Specificity for KDM1A inhibitors and nuclear KDMs
Having identified GGA-induced translocation of nuclear KDM1A for the first time, we next considered whether this cytoplasmic translocation could be induced by treatment with a similar diterpenoid of ATRA (all-trans retinoic acid) that lacks KDM1A-inhibitory activity, or weak inhibitor isoprenoids of GGOH (geranylgeraniol) and FA (farnesoic acid). 14 ATRA did not induce cytoplasmic translocation of nuclear KDM1A.
GGOH and FA less-efficiently but significantly induced cytoplasmic release of nuclear KDM1A ( Fig. 2A) , suggesting that the translocation response of nuclear KDM1A is associated with its inhibitor activity.
Next, we tested whether GGA or TCP could induce cytoplasmic translocation of another nuclear KDM, KDM5A, which acts cooperatively with KDM1A to remove methyl groups from histone H3 lysine 4. As shown in the upper images in 
Release of nuclear KDM1A by GGA or TCP under cell-free conditions
We recently reported that GGA directly inhibits recombinant human KDM1A. 14 TCP acts as an irreversible inhibitor forming a covalent adduct with the FAD cofactor of the KDM1A enzyme. 24 In the present study, we examined the direct effect of these inhibitors on the release of KDM1A protein from the nucleus. Dose-dependent release of the protein from the nuclear fraction was observed with either GGA or TCP (Fig.   3A ).
Finally, we investigated GGA-induced changes in the cellular level of KDM1A protein to understand why KDM1A translocates out of the nucleus upon GGA treatment. 
Discussion
The present study demonstrates for the first time that small chemical inhibitors of KDM1A, GGA and TCP, induce cytoplasmic translocation of nuclear KDM1A protein from the nucleus in human hepatoma-derived cells. Taking into account the fact that KDM1A has been identified as a component of the corepressor for element 1-silencing transcription factor (CoREST) corepressor complex 25 and is a recognized nuclear marker protein 26 , the present finding of KDM1A inhibitor-induced translocation of KDM1A from the nucleus to the cytoplasm may be important both for inhibitor screening and for understanding the biology of KDM1A. In this report, we propose and discuss the biological significance of the transfer of KDM1A protein from the nucleus to the cytoplasm in response to KDM1A inhibitors.
In the present study, we confirmed strict nuclear localization of KDM1A protein in control human hepatoma-derived HuH-7 cells (Fig. 1 ). KDM1A was discovered in 2004 as a nuclear homolog of amine oxidases that functions as a histone demethylase and transcriptional corepressor, 3 which indicates that the enzyme originally resides in chromatin and plays a role in the repression of gene expression through epigenetic mechanisms. Here, however, we describe the striking finding that the KDM1A inhibitors GGA and TCP immediately dislodged KDM1A from the nucleus to the cytoplasm, suggesting that these inhibitors not only inhibited enzyme activity, but moved the enzyme itself to a location where epigenetic regulation was not possible.
Therefore, these two inhibitors block the function of the enzyme via a dual mechanism.
The question then arises as to what types of compounds can induce this transfer of the KDM1A enzyme from the nucleus to the cytoplasm. We tested the ability of the GGA-analogous compounds GGOH (an alcoholic derivative of GGA), ATRA (a monocyclic and conjugated derivative of GGA) and FA (an acyclic sesquiterpenoid acid, whereas GGA is an acyclic diterpenoid acid) to induce the cytoplasmic translocation of nuclear KDM1A. ATRA, which exhibit no KDM1A-inhibitory activity, failed to induce translocation of the enzyme and both GGOH and FA with less inhibitory activity 14 slightly but significantly translocated the enzyme (Fig. 2) , suggesting that the activity of the inhibitors may be associated with the dislodging activity. Hence, one can reasonably speculate that an assay for drug-induced translocation of nuclear KDM1A
could be developed to screen for KDM1A inhibitors without the need for measurement of the enzyme activity.
A second question is whether these enzyme inhibitors dislodge only KDM1A from the chromatin. We investigated another lysine-specific demethylase, KDM5A, which plays a cooperative role in demethylation of histone H3 lysine 4 in conjunction with KDM1A. 27 We confirmed that KDM5A localized to the nucleus. Neither GGA nor TCP induced translocation of the nuclear KDM5A to the cytoplasm under the same conditions as those under which these inhibitors dislodged nuclear KDM1A. This indicates that the inhibitors' effect on subcellular localization is specific for KDM1A.
However, it currently remains unclear whether other components, such as HDAC1/2, may be released from the CoREST complex by GGA or TCP treatment.
Recruitment of KDM1A to chromatin has been extensively and thoroughly explored [28] [29] [30] [31] [32] , but little research has been conducted on the unloading of KDM1A from chromatin. Particularly relevant among the previous studies on the subcellular distribution of KDM1A is a report by Nair et al, which describes cell cycle-dependent association and dissociation of KDM1A with chromatin. 23 Specifically, KDM1A is recruited to the chromatin of cells in the G 1 /S/G 2 phases and is displaced from the chromatin of M-phase cells. We confirmed that in M-phase cells stained with pHH3
antibody, KDM1A protein was distributed throughout the cell (Fig. 1D) , whereas in the other non-M-phase cells KDM1A protein remained in the nucleus. However, in cells treated with GGA or TCP, KDM1A was distributed throughout the whole cell interior as in control M-phase cells, regardless of cell cycle stage. We can therefore conclude that GGA and TCP did not increase the number of cells in M-phase, and did act on cells in the G 1 /S/G 2 phases to induce translocation of nuclear KDM1A to the cytoplasm. Taking these findings together with the fact that anti-pHH3 antibody recognizes phosphorylated Ser10 on histone H3 and that introduction of a negatively charged phosphate group on Ser10 completely abolishes KDM1A activity 33 , one can reasonably speculate that a KDM1A inhibitor may unload the enzyme from chromatin.
Finally, we should discuss how GGA and TCP specifically dislodged KDM1A from the nucleus. We speculated that direct binding of GGA or TCP to nuclear KDM1A might cause release of the enzyme from the chromatin. By analyzing the nuclear fraction containing KDM1A, we demonstrated that GGA-and TCP-mediated release of KDM1A from the nuclear fraction to the supernatant was dose-dependent (Fig. 3A) .
Both GGA 14 and TCP 24 directly inhibit recombinant KDM1A enzyme activity and are thought to bind to the substrate-binding site of the enzyme. The structures of free and
CoREST-bound KDM1A are virtually identical, with only a small difference in the orientations of two α-helices of the tower domain relative to the amine oxidase domain of KDM1A. 34 In this context, it is difficult to speculate as to whether direct binding of GGA or TCP to the substrate-binding site in the amine oxidase domain of KDM1A
would affect interaction between the enzyme and the CoREST protein.
Other inhibitor-induced conformational changes of KDM1A may be involved in its unloading from the nuclear fraction in the cell-free experiment. We should also consider the metabolic fate of the KDM1A exported in response to treatment with its inhibitor. Fig.   3B clearly shows that GGA-induced downregulation of the cellular KDM1A level was time-dependent. This may potentially be explained by polyubiquitination and efficient degradation of the dislodged KDM1A from the chromatin by the proteasome system. 35 The present study clearly demonstrates that the KDM1A inhibitors GGA and TCP induce cytoplasmic translocation of nuclear KDM1A. This biological process has potential to be useful for screening promising cancer-preventive epigenetic therapeutic agents targeting KDM1A, and further work to this end is warranted.
Material and Methods
Materials
GGA and FA were generous gifts from Kuraray (Okayama, Japan). GGOH and TCP hydrochloride were purchased from Sigma Aldrich (St. Louis, MO, USA). ATRA was obtained from Wako Pure Chemicals (Osaka, Japan).
Cell culture and treatment
Human hepatoma-derived HuH-7 cells were seeded at 1. 
Cell-free analysis of drug-induced release of nuclear KDM1A
Nuclear fractions of HuH-7 cells were prepared for cell-free analysis of inhibitor-induced translocation of nuclear KDM1A using a CelLytic nuclear kit (Sigma Aldrich). The nuclear pellets were gently suspended in PBS-T (PBS containing 0.1%
Triton-X 100), then GGA or TCP (final concentrations 0-20 µM) was added to each nuclear suspension (60 µg protein/tube, proteins were quantified by Bradford assay, Bio-Rad, Hercules, CA, USA), and samples were gently vortexed and incubated overnight at 4°C. The supernatants were centrifuged at 1000 × g for 10 min, separated by SDS-PAGE, and analyzed by western blotting with anti-KDM1A antibody as described below.
Western blotting
The eluted proteins in equal volume were separated by SDS-PAGE and transferred to semi-dry blotted polyvinylidene fluoride membranes (Bio-Rad). The membranes were probed with a rabbit polyclonal antibody against KDM1A (Cell Signaling Technology), and then with horseradish peroxidase (HRP)-labeled secondary antibody (GE Healthcare, Tokyo, Japan). KDM1A bands were detected with Immobilon Western Chemiluminescent HRP substrate (Merck Millipore Japan) using an Image Quant LAS 4000 (GE Healthcare).
Statistical analysis
Differences between two groups were assessed by Student t-test and were considered statistically significant if P value was <0.05.
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